Prolia prevents fractures in post-menopausal women with osteoporosis and in men with prostate cancer that are in anti-hormonal treatment. Because of its price, Prolia can not be considered the first-line drug for treatment of osteoporosis.
Treatment with Prolia can be attempted in patients where alendronate cannot be used, if the patient has side effects or does not respond to treatment. Compared to Aclasta, which is administered IV., the fact that Prolia is administered subcutaneously can be an advantage, since the patient or caregiver is able to administer the drug. Patients in treatment with Prolia should be taking an adequate amount of calcium and vitamin D.
Prolia can in rare cases result in transient hypocalcaemia. Prolia can possibly increase the risk of certain infections. In men with prostate cancer, an increased risk of basal cell carcinomas and cataracts has been observed.
Prolia was marketed on June 28th, 2010.
The Institute for Rational Pharmacotherapy, September 1st, 2010.